Genetics Institute, Inc.

Radius Health, Inc.

Radius Pharmaceuticals, Inc.

3m Innovative Properties Company

Ellipses Pharma Limited

Other

Kindeva Drug Delivery, L.p.

3m Innovative Properties Company, a Wholly Owned Subsidiary of 3m Company

Gary Hattersley

Jamal Saeh

Ying Di Zhang

Vicki A Rosen

Joan T Moseman

Lisa Dick

Alan Harris

Daniel Dohmeier

Kenneth Brown

Chris P Miller

Ziyang Yu

Teeru Bihani

Ehab Hamed

Edward R LaVallie

Neil M Wolfman

Lisa A Racie

Bart Henderson

C Richard Lyttle

Elisabeth Ann Morris

Ying Zhang

Amy S Determan

Fiona Garner

Kris J Hansen

Joan Moseman

Kenneth E Brown

Daniel M Dohmeier

Lisa A Dick

A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.

AR+breast cancer treatment methods

Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.

Methods for treating cancer

Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure: or a salt or solvate thereof.

AR+ breast cancer treatment methods

Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.

Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Formulations of abaloparatide, transdermal patches thereof, and uses thereof

A medical device comprising a composition comprising a therapeutically active amount of active agent, a zinc compound, and an array of microneedles. The zinc compound may be selected from the group consisting of zinc, pharmaceutically acceptable salts of zinc, and mixtures thereof. At least a portion of the composition is present as a coating on at least a portion of the microneedles. Methods of delivering a therapeutically active agent to a mammal using compositions of the disclosure are also included.

Zinc compositions for coated microneedle arrays

The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.

Treatment of vasomotor symptoms with selective estrogen receptor modulators

Purified human SDF-5 proteins and processes for producing them are disclosed. DNA molecules encoding the human SDF-5 proteins are also disclosed. The proteins may be used in regulating the binding of Wnt genes to their receptor. In preferred embodiments, the proteins may be used for inducing formation, growth, differentiation, proliferation and/or maintenance of chondrocytes and/or cartilage tissue, and for other tissue repair, such as pancreatic tissue repair.

Human SDF-5 protein and compositions

Compositions of proteins with cartilaginous tissue inducing and maintenance activity are disclosed. The compositions are useful in the treatment of osteoarthritis, cartilage defects and in related tissue repair.

Cartilage induction by bone morphogenetic proteins

Compositions of proteins with chondrocyte and cartilaginous tissue inducing activity, as well as method of using those compositions, are disclosed. The compositions comprise one or more proteins of the transforming growth factor-.beta. (TGF-.beta.) superfamily of proteins, particularly bone morphogenetic proteins (BMPs), in combination with parathyroid hormone related polypeptide (PTHrP) or an equivalent PTH-like polypeptide. The compositions and methods are useful in the treatment of osteoarthritis, cartilage defects and in related tissue repair.

Compositions comprising bone morphogenic proteins and truncated

Growing community of inventors

Stow, MA, United States of America

Gary Hattersley